Eupraxia Pharmaceuticals Appoints Chief Business Officer

VICTORIA, BC,?Nov. 1, 2022 - Eupraxia Pharmaceuticals Inc.?("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has appointed Paul Brennan to the role of Chief Business Officer ("CBO").

Mr. Brennan will work closely with the executive management team to secure partnership opportunities to help advance the Company's pipeline of drug candidates.

"Paul is an experienced and successful business development executive with decades of biotech experience in Canada and internationally," said Dr. James Helliwell, CEO of Eupraxia. "The company continues to make progress in pipeline development, having recently added a second Phase 2 program in eosinophilic esophagitis. As we continue to advance additional pipeline candidates, we believe development and commercialization partnerships will offer a potentially non-dilutive means to resource and fund these programs, as well as important external validation of the underlying drug candidate prospects. With a focus on optimizing value for shareholders and fully resourcing all pipeline projects, we believe Paul will be instrumental in the execution of this next stage of growth for the Company."

Paul Brennan Background

Mr. Brennan has more than 30 years?experience in the pharma and biotech?industries where he has held several executive positions in?general?management and/or business development including at NervGen Pharma, Aquinox Pharmaceuticals, Arbutus Biopharma (formerly Tekmira Pharmaceuticals), Aspreva Pharmaceuticals and AnorMED.

He has participated in?the development and/or?commercialization of more than 10 products that have advanced from clinical development through to?regulatory?approval in either the U.S. or Europe and has been?involved in several billions of dollars worth of business development and financing?transactions.

Notable?transactions involving Mr. Brennan include the sale of Aspreva to Vifor Pharma for $915 million, the sale of AnorMED to Genzyme for $580 million and the merger of Tekmira and OnCore Biopharma to form Arbutus Biopharma, valued at more than $1 billion.

He has also served in senior business development and regulatory affairs roles with AstraZeneca plc, working in Sweden, the United Kingdom and Canada. Mr. Brennan holds a master's degree in?Neurophysiology from Queen's University in Kingston.

For more information, please view the Company's press release here:

https://eupraxiapharma.com/news/news-details/2022/Eupraxia-Pharmaceuticals-Appoints-Chief-Business-Officer/default.aspx